Skip to main content
Eligibility
for people ages 18 years and up
Location
at San Francisco, California and other locations
Dates
study started
estimated completion:
Principal Investigator

Description

Summary

This is a phase 1, multicenter, nonrandomized, open-label, dose escalation study. The study will be conducted in 2 stages, Dose Escalation and Dose Expansion. The Dose Escalation phase will include patients with solid tumors (including melanoma) who have failed or are not candidates for standard therapies or for whom no approved therapy is available. The Dose Expansion phase will include patients with metastatic melanoma.

Official Title

An Open-Label, Phase 1, Dose Escalation Study of MLN2480 in Patients With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion Phase in Patients With Metastatic Melanoma

Keywords

Melanoma Metastatic Melanoma Solid Tumor

Eligibility

You can join if…

Open to people ages 18 years and up

  • Informed consent
  • Male or female patients 18 years or older
  • Dose Escalation phase: Patients with solid tumors (including melanoma) who have failed or are not candidates for standard therapies of for whom no approved therapy is available
  • Dose Expansion phase: Metastatic melanoma (locally advanced or metastatic melanoma)
  • Dose Expansion phase: At least 1 measurable lesion which has not been treated previously with radiotherapy. A newly arising lesion in a previously irradiated field is acceptable
  • For patients undergoing biopsy procedures: Prothrombin time (PT) and activated partial thromboplastin time (aPTT) must be within the normal range
  • Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1
  • Adequate tissue sample from either archival formalin-fixed paraffin-embedded (FFPE)tumor tissue or new biopsy of tumor
  • Previous chemotherapy, immunotherapy, and hormone therapy must be completed at least 4 weeks prior to the administration of MLN2480 and radiation must be completed at least 3 weeks prior to the administration of MLN2480; all associated toxicity must be resolved to ≤ Grade 1
  • Expected survival time of at least 3 months in the opinion of the investigator
  • Patients who do not have hypo- or hyperthyroidism
  • Ability to swallow and retain oral medication
  • Female patients who are post menopausal for at least 1 year, surgically sterile, or agree to practice 2 effective methods of contraception through 3 months after the last dose of study drug or agree to practice true abstinence
  • Male patients who, even if surgically sterilized, agree to practice effective barrier contraception through 3 months after the last dose of alisertib or agree to practice true abstinence

You CAN'T join if...

  • History of any major disease that might interfere with safe protocol participation
  • Dose Expansion phase: Previous treatment with RAF or MEK inhibitors
  • Laboratory values as specified in study protocol
  • Current enrollment in any other investigational treatment study
  • Evidence of current uncontrolled cardiovascular conditions within the past 6 months
  • Prior investigational agents for malignant or non-malignant disease within 4 weeks prior to Day 1
  • Active hepatitis or human immunodeficiency virus (HIV) infection
  • Active bacterial or viral infection
  • Female patients who are pregnant or currently breastfeeding
  • Major surgery within 28 days of Day 1
  • Refractory nausea and vomiting, malabsorption, or significant bowel or stomach resection
  • Inability to comply with study requirements
  • Other unspecified reasons that, in the opinion of the investigator or Millennium,make the patient unsuitable for enrollment

Locations

  • San Francisco, California, USA
  • Denver, Colorado, USA
  • Augusta, Georgia, USA
  • Indianapolis, Indiana, USA
  • New York, New York, USA
  • Easton, Pennsylvania, USA
  • Philadelphia, Pennsylvania, USA
  • San Antonio, Texas, USA
  • Lakewood, Washington, USA
  • Bristol, Avon, United Kingdom
  • Cambridge, Cambridgeshire, United Kingdom
  • Chelmsford, Essex, United Kingdom
  • London, Greater London, United Kingdom
  • Manchester, Greater Manchester, United Kingdom
  • Oxford, Oxfordshire, United Kingdom
  • Newcastle upon Tyne, Tyne & Wear, United Kingdom

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Millennium Pharmaceuticals, Inc.
ID
NCT01425008
Phase
Phase 1
Lead Scientist
Adil Daud
Study Type
Interventional
Last Updated
December 2016